Patents Examined by Delia M. Ramirez
  • Patent number: 11236374
    Abstract: The present disclosure relates to modified homoserine dehydrogenase and a method for producing a homoserine-derived L-amino acid using the same.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: February 1, 2022
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Hyo Jin Kim, Lan Huh, Sang Jo Lim, Hyun Ah Kim, Hyoung Joon Kim, Chang il Seo, Seung Bin Lee, Ji Sun Lee
  • Patent number: 11225649
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: January 18, 2022
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 11220665
    Abstract: Provided is a method for producing a high-density filamentous fungal pellet. A method for producing a filamentous fungal pellet, comprising a step of germinating spores of a filamentous fungus in a culture medium containing a cationic polymer.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 11, 2022
    Assignee: KAO CORPORATION
    Inventors: Takeshi Sakamoto, Yutaka Irie
  • Patent number: 11208671
    Abstract: A recombinant cell and a method of producing itaconic acid using such recombinant cell. The recombinant cell is of the genus Methylorubrum and includes a first polynucleotide sequence as defined in SEQ ID NO: 1 or a homologue thereof operably linked to a regulatory sequence.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: December 28, 2021
    Assignee: City University of Hong Kong
    Inventors: Chee Kent Lim, Patrick Kwan Hon Lee
  • Patent number: 11208644
    Abstract: Provided herein are recombinant glycoproteins (e.g., recombinant human ?-galactosidase-A proteins) with an altered (e.g., improved) glycosylation profile, and pharmaceutical compositions and kits including one or more of these proteins. Also provided are methods of generating a mammalian cell useful for recombinant expression of a glycoprotein (e.g., recombinant human ?-galactosidase-A), methods of producing recombinant glycoproteins, and methods of treatment that include administering to a subject at least one of the recombinant glycoproteins (e.g., recombinant human ?-galactosidase-A protein).
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: December 28, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Karen Lee, Christopher Hwang, Christine DeMaria
  • Patent number: 11198767
    Abstract: The present invention relates to plastic composition comprising at least one polyester, biological entities having a polyester-degrading activity and at least an anti-acid filler, wherein the biological entities represent less than 11% by weight, based on the total weight of the plastic composition, and uses thereof for manufacturing biodegradable plastic articles.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 14, 2021
    Assignee: CARBIOS
    Inventors: Elodie Guemard, Michel Chateau, Alain Marty
  • Patent number: 11198890
    Abstract: The subject invention relates to a process of preparing (R)-3-hydroxybutyric acid or a salt thereof by one-step fermentation with a nonpathogenic microorganism. The fermentation of (R)-3-hydroxybutyric acid was performed by supplying with certain carbon and nitrogen sources. These microorganisms include a Glutamic acid Bacterium HR057 strain or one type of genetically engineered Corynebacterium Glutamicum.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: December 14, 2021
    Assignee: NNB Nutrition USA, LLC
    Inventors: Kylin Liao, Wenchao Fan
  • Patent number: 11186858
    Abstract: The present invention relates to a method of increasing biosimilarity of a TNF ? binding protein to a reference TNF ? binding protein by modifying the charge profile of the binding protein produced by cell culture in a cell culture medium, by making an adjustment to a cell culture condition The adjustment is an increase in the concentration of a metal ion in the cell culture medium and the adjustment occurs on one or more days during the cell culture method, whereby the adjustment in the cell culture condition results in the modification of the charge profile of the binding protein. The present invention also relates to a biosimilar protein obtainable by such a process.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: November 30, 2021
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Thomas Solacroup, Matthieu Stettler, Martin Jordan, Hervé Broly
  • Patent number: 11162127
    Abstract: Herein is reported a method for producing an enzymatic conjugation product of three polypeptides comprising the simultaneous incubation of i) a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 20, wherein X can be any amino acid residue), a second polypeptide comprising the amino acid sequence LPXTA (SEQ ID NO: 31, wherein X can be any amino acid residue), a third polypeptide that has two N-termini whereby the polypeptide has an oligo-glycine Gm (m=2 (SEQ ID NO: 22), or 3 (SEQ ID NO: 23), or 4 (SEQ ID NO: 24), or 5 (SEQ ID NO: 25)) amino acid sequence at its first N-terminus and an oligo-alanine Am (m=2 (SEQ ID NO: 26), or 3 (SEQ ID NO: 27), or 4 (SEQ ID NO: 28), or 5 (SEQ ID NO: 29)) amino acid sequence at its second N-terminus, a fourth polypeptide with sortase activity whereby the polypeptide is derived from Staphylococcus aureus sortase A, and a fifth polypeptide with sortase activity whereby the polypeptide is derived from Streptococcus pyogenes sortase A and the recovering of the c
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: November 2, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Dieter Heindl, Erhard Kopetzki, Georg Tiefenthaler
  • Patent number: 11161899
    Abstract: Disclosed herein are split inteins, fused proteins of split inteins, and methods of using split inteins to efficiently purify and modify proteins of interest.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: November 2, 2021
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Tom W. Muir, Miquel Vila-Perello, Zhihua Liu, Neel H. Shah
  • Patent number: 11142750
    Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced specificity and/or efficiency of indel formation, when compared to the first-generation meganuclease HBV 11-12×.26. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or hepatocellular carcinoma.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: October 12, 2021
    Assignee: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Janel Lape, Victor Bartsevich, Hui Li
  • Patent number: 11104889
    Abstract: Provided are a group of phi29 DNA polymerase mutants having increased thermal stability and use thereof. The phi29 DNA polymerase mutants are proteins obtained by performing point mutation A and/or point mutation B and/or point mutation C on phi29 DNA polymerase, the point mutation A meaning that an amino acid residue M at position 97 of the phi29 DNA polymerase is mutated to other amino acid residue, the point mutation B meaning that an amino acid residue L at position 123 of the phi29 DNA polymerase is mutated into other amino acid residue, and the point mutation C meaning that an amino acid residue E at position 515 of the phi29 DNA polymerase is mutated to other amino acid residue. The stability of the phi29 DNA polymerase mutants is higher than that of a wild-type phi29 DNA polymerase.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: August 31, 2021
    Assignee: MGI TECH CO., LTD.
    Inventors: Zhougang Zhang, Huanhuan Liu, Yue Zheng, Yujun Zhou, Xing Liu, Yuliang Dong, Chongjun Xu, Wenwei Zhang
  • Patent number: 11104715
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: August 31, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Mastrogiacomo, Shunhai Wang, Ning Li
  • Patent number: 11104922
    Abstract: Methods to prepare vegetable oil compositions having an elevated ethyl ester content are provided.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: August 31, 2021
    Assignee: POET Research, Inc.
    Inventors: Alexander T. McCurdy, Steven T. Bly, Stephen M. Lewis, Benjamin P. Gacke, Brandon James Breitling
  • Patent number: 11098333
    Abstract: The present disclosure relates to an ATP phosphoribosyltransferase (HisG) protein and a method for producing histidine using the same.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: August 24, 2021
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Myung Keun Park, Nara Kwon, Jin Nam Lee
  • Patent number: 11060115
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 13, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, Rutgers, the State University of New Jersey, Skolkovo Institute of Science and Technology, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Konstantin Severinov, Feng Zhang, Yuri I. Wolf, Sergey Shmakov, Ekaterina Semenova, Leonid Minakhin, Kira S. Makarova, Eugene Koonin, Silvana Konermann, Julia Joung, Jonathan S. Gootenberg, Omar O. Abudayyeh, Eric S. Lander
  • Patent number: 11058724
    Abstract: The present disclosure provides D1L3 enzymes having complete or partial C-terminal deletions of the basic domain (BD), which have substantially enhanced chromatin-degrading activity. In various aspects, the invention provides chromatinase enzyme therapy, which is optionally provided by delivering polynucleotides encoding chromatinases such as D1L3, or by delivering host cells expressing and secreting the same.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: July 13, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • Patent number: 11053482
    Abstract: The invention relates to the field of genetic engineering tools, methods and techniques for gene or genome editing. Specifically, the invention concerns isolated polypeptides having nuclease activity, host cells and expression vectors comprising nucleic acids encoding said polypeptides as well as methods of cleaving and editing target nucleic acids in a sequence-specific manner. The polypeptides, nucleic acids, expression vectors, host cells and methods of the present invention have application in many fields of biotechnology, including, for example, synthetic biology and gene therapy.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: July 6, 2021
    Assignee: WAGENINGEN UNIVERSITEIT
    Inventor: John Van Der Oost
  • Patent number: 11046938
    Abstract: Described herein are recombinant yeast cells expressing a xylulose kinase (XK) which are suitable for fermentation of pentoses. Also described are recombinant yeast cells with higher tolerance to formic and/or acetic acid and suitable for fermentation of pentoses. Also described are recombinant yeast cells expressing an enolase, a phosphofructokinase beta subunit, a 6-phosphofructo-2-kinase, a glucose-6-phosphate isomerase, a phosphoglycerate mutase and/or a triose-phosphate isomerase, and suitable for fermentation of pentoses. Also described are recombinant yeast cells expressing a phosphoglucomutase and/or phosphoribomutase which are suitable for fermentation of pentoses. Further described are methods of using or producing such recombinant yeast cells and related materials.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 29, 2021
    Assignee: Novozymes A/S
    Inventors: Kaisa Karhumaa, Malin Sendelius, Violeta Sánchez I Nógue
  • Patent number: 11034981
    Abstract: The present invention relates to the field of fungal production fatty alcohols. More specifically, the present invention relates to genetically modified host cells, nucleic acid constructs and culture medium for the production of fatty alcohols in Rhodosporidium.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 15, 2021
    Assignee: TEMASEK LIFE SCIENCES LABORATORY LIMITED
    Inventors: Lianghui Ji, Yanbin Liu, Chong Mei John Koh, Sihui Amy Yap, Si Te Ngoh